What are Aldose reductase inhibitor drugs?

Aldose reductase inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Aldose reductase). 1 are currently marketed, with 2 more in clinical development.

What are the marketed Aldose reductase inhibitor drugs?

Marketed Aldose reductase inhibitor drugs include AO-128.

Aldose reductase inhibitor

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 marketed 2 in Phase 3

This page covers all Aldose reductase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Aldose reductase.

Targets

Aldose reductase

Marketed (1)

AO-128 · Takeda · Diabetes
AO-128 is a selective inhibitor of aldose reductase, an enzyme in the polyol pathway that converts glucose to sorbitol.

Phase 3 pipeline (2)

AT-007 · Applied Therapeutics, Inc. · Endocrinology / Diabetes
AT-007 is a small molecule that inhibits aldose reductase, the first enzyme in the polyol pathway, to reduce sorbitol accumulation and prevent diabetic complications.
ranirestat, (AS-3201) · Sumitomo Pharma Co., Ltd. · Endocrinology / Diabetes
Ranirestat inhibits aldose reductase, the first enzyme in the polyol pathway, to reduce sorbitol accumulation and prevent diabetic complications.

Patent intelligence

aldose reductase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates